Neuphoria Therapeutics signed a definitive merger agreement with Scancell under which each Neuphoria share will convert into Scancell ADSs plus one CVR, targeting post-close ownership of about 11.1% for Neuphoria holders. Closing is subject to shareholder approvals, Nasdaq listing of Scancell ADSs, an effective Form F-4 and at least $75 million of concurrent financing. Supporting agreements include reciprocal voting commitments, planned insider lock-ups at closing, a CVR arrangement sharing 100% of net proceeds from designated assets, a PIPE at $0.1205 per security, UK placing and retail offers targeting up to $15 million combined, and a warrant amendment with Armistice to allow equity settlement of any excess cash-out value.
Agreement 1: Neuphoria Therapeutics to Merge With Scancell; Holders to Receive ADSs Plus CVRs
- Agreement type: Agreement and Plan of Merger
- Counterparty: Scancell Holdings
- Signed / Effective: Jul 23 2026 / same
- Duration / Termination: Until closing
- Reason: Combine pipelines and access broader capital markets
Agreement 2: Neuphoria Shareholders Sign Voting and Support Deals Backing Scancell Merger
- Agreement type: Voting and Support Agreements
- Counterparty: Scancell Holdings
- Signed / Effective: Jul 23 2026 / same
- Duration / Termination: Until closing
- Reason: Secure stockholder approval for the merger
Agreement 3: Scancell Holders Enter Voting and Support Deed to Advance Neuphoria Combination
- Agreement type: Parent Voting and Support Deed
- Counterparty: Scancell Holdings
- Signed / Effective: Jul 23 2026 / same
- Duration / Termination: Until closing
- Reason: Ensure requisite Scancell shareholder approvals
Agreement 4: Neuphoria and Scancell Plan Insider Lock-Ups at Merger Closing
- Agreement type: Lock-Up Agreements
- Counterparty: Directors, Officers and Stockholders
- Signed / Effective: N/A / N/A
- Duration / Termination: Restricted period post-closing
- Reason: Promote post-merger trading stability
Agreement 5: Scancell to Enter CVR Agreement Delivering 100% of Net Proceeds From Legacy Assets
- Agreement type: Contingent Value Rights Agreement
- Counterparty: Rights Agent
- Signed / Effective: N/A / N/A
- Duration / Termination: 15 years for specified streams
- Reason: Share potential upside from non-core assets
Agreement 6: Scancell Secures PIPE at $0.1205 Per Security to Support Neuphoria Merger
- Agreement type: PIPE Subscription Agreements
- Counterparty: Institutional and Individual Investors
- Signed / Effective: Jul 23 2026 / same
- Duration / Termination: At will
- Reason: Fund closing and meet financing condition
Agreement 7: Scancell Launches $12M UK Placing and Up to $3M Retail Offer Ahead of Merger
- Agreement type: UK Placing Agreement and Retail Offer Arrangement
- Counterparty: Panmure Liberum and Winterflood
- Signed / Effective: Jul 23 2026 / same
- Duration / Termination: At will
- Reason: Augment capital base and broaden investor access
Agreement 8: Neuphoria Amends Armistice Warrant; Excess Cash-Out Payable in Scancell Equity
- Agreement type: Warrant Amendment Letter Agreement
- Counterparty: Armistice Capital
- Signed / Effective: Jul 20 2026 / same
- Duration / Termination: At will
- Reason: Facilitate merger and reduce potential cash outflows
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.